ANGELLO: Knee Osteoarthritis and Balneotherapy

Sponsor
CEN Biotech (Industry)
Overall Status
Completed
CT.gov ID
NCT05819437
Collaborator
COMPAGNIE EUROPEENNE DES BAINS (Other)
173
1
2
24.8
7

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to assess the efficacy of a 18-day balneotherapy program in the rheumatology indication in patients presented with knee osteoarthritis. The main questions of the study aims to answer are how balneotherapy improves functional incapacity and the disorders (pain, joint stiffness) induced by osteoarthritis of the knee, and thus improves patients' quality of life.

Participants are randomly assigned in control or treatment (spa) groups. All receive standard of care for knee osteoarthritis throughout the study. Balneotherapy program consists of 18-days of spa treatment with Mineral Water of Saint Jean d'Angely. Functional incapacity, disorders and quality of life induced were measured at baseline and then 6 months later.

Variation from baseline were compared in control and treatment groups to assess the efficacy of the balneotherapy program.

Condition or Disease Intervention/Treatment Phase
  • Other: Balneotherapy program
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
173 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled Trial, monocentricRandomized controlled Trial, monocentric
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Effectiveness of a 3-week Balneotherapy Program With Mineral Water of Saint Jean d'Angely in Knee Osteoarthritis: A Superiority, Randomised, Controlled Study Versus Standard of Care Alone
Actual Study Start Date :
Aug 26, 2020
Actual Primary Completion Date :
Jul 3, 2021
Actual Study Completion Date :
Sep 20, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: CONTROL

Standard of care for knee osteoarthritis

Experimental: BALNEOTHERAPY PROGRAM

3-week balneotherapy program with Mineral Water of Saint Jean d'Angely in addition to standard of care for knee osteoarthritis

Other: Balneotherapy program
Whirlpool bath, bath with immersion showers, poultice application and underwater massage. The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion. The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes). The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes. The water used is a mixed sulphated Natural Mineral Water, collected by drilling the "capuchins" at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C.

Outcome Measures

Primary Outcome Measures

  1. Variation from baseline in physical function subscale of the WOMAC at 6 months [Baseline (D1) and final (6 months)]

    Physical function subscale of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered questionnaire that consists in 17 items: (17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties. The 100-normalized subscale score ranges from 0 (none) to 100 (worse functional limitations).

Secondary Outcome Measures

  1. Variation from baseline in physical function subscale of the WOMAC at 3 months [Baseline (D1) and final (3 months)]

    Physical function subscale of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered questionnaire that consists in 17 items: (17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties. The 100-normalized subscale score ranges from 0 (none) to 100 (worse functional limitations).

  2. Variation from baseline in pain subscale of the WOMAC at 3 months [Baseline (D1) and final (3 months)]

    Pain subscale of the WOMAC is a self-administered questionnaire that consists in 5 items: during walking, using stairs, in bed, sitting or lying, and standing upright. The 100-normalized subscale score ranges from 0 (none) to 100 (worse pain limitations).

  3. Variation from baseline in pain subscale of the WOMAC at 6 months [Baseline (D1) and final (6 months)]

    Pain subscale of the WOMAC is a self-administered questionnaire that consists in 5 items: during walking, using stairs, in bed, sitting or lying, and standing upright. The 100-normalized subscale score ranges from 0 (none) to 100 (worse pain limitations).

  4. Variation from baseline in stiffness subscale of the WOMAC at 3 months [Baseline (D1) and final (3 months)]

    Stiffness subscale of the WOMAC is a self-administered questionnaire that consists in 2 items: during walking, using stairs, in bed, sitting or lying, and standing upright. The 100-normalized subscale score ranges from 0 (none) to 100 (worse stiffness limitations).

  5. Variation from baseline in stiffness subscale of the WOMAC at 6 months [Baseline (D1) and final (6 months)]

    Stiffness subscale of the WOMAC is a self-administered questionnaire that consists in 2 items: during walking, using stairs, in bed, sitting or lying, and standing upright. The 100-normalized subscale score ranges from 0 (none) to 100 (worse stiffness limitations).

  6. Variation from baseline in WOMAC total score at 3 months [Baseline (D1) and final (3 months)]

    The scores for each subscale are summed up to calculate the total WOMAC score. The 100-normalized score ranges from 0 (none) to 100 (worse limitations).

  7. Variation from baseline in WOMAC total score at 6 months [Baseline (D1) and final (6 months)]

    The scores for each subscale are summed up to calculate the total WOMAC score. The 100-normalized score ranges from 0 (none) to 100 (worse limitations).

  8. Variation from baseline in pain-induced knee osteoarthritis intensity at 3 months [Baseline (D1) and final (3 months)]

    Pain intensity is measured using a 0 (no pain)-100 (Worse pain) Visual Analogic Scale (VAS).

  9. Variation from baseline in pain-induced knee osteoarthritis intensity at 6 months [Baseline (D1) and final (6 months)]

    Pain intensity is measured using a 0 (no pain)-100 (Worse pain) Visual Analogic Scale (VAS).

  10. Number of participants achieving minimal clinically important improvement (MCII) at 3 months [3 months]

    MCII is defined as 19.9 mm or greater on the VAS pain scale and/or 9.1 points or greater on the WOMAC physical function subscale normalized to a 0-100 score, and no knee surgery

  11. Number of participants achieving minimal clinically important improvement (MCII) at 6 months [6 months]

    MCII is defined as 19.9 mm or greater on the VAS pain scale and/or 9.1 points or greater on the WOMAC physical function subscale normalized to a 0-100 score, and no knee surgery

  12. Number of participants presented with acceptable symptom state (ASS) at 3 months [3 months]

    ASS is defined as VAS pain 32 mm or less or WOMAC function subscale normalized to a 0-100 score of 31 points or less.

  13. Number of participants presented with acceptable symptom state (ASS) at 6 months [6 months]

    ASS is defined as VAS pain 32 mm or less or WOMAC function subscale normalized to a 0-100 score of 31 points or less.

  14. Changes in participants quality of life at 3 months [3 months]

    Quality of life is measured using EUROQOL (EQ-5D-3L) questionnaire.The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

  15. Changes in participants quality of life at 6 months [6 months]

    Quality of life is measured using EUROQOL (EQ-5D-3L) questionnaire.The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

  16. Frequency of adverse events throughout the study [From inclusion to the final visit at 6 months]

    Adverse events are described using MedDRA and each event frequency is calculated.

  17. Participants' opinion with their symptoms related to knee osteoarthritis at 6 months [6 months]

    Opinion is measured using a 5-point Likert scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Knee osteoarthritis with Kellgren and Lawrence stage 2 to 4 evidenced by a knee X-ray examination in the past 3 years);

  • 100-normalized score of the WOMAC physical function subscale of 30 or greater;

  • Available for balneotherapy program and the 6-month study follow-up;

  • Signed inform consent;

  • with health insurance affiliation.

Exclusion Criteria:
  • Presented with balneotherapy contra-indication;

  • Having had spa treatment in the past 6 months or intra-articular corticosteroid injection within the previous 90 days or hyaluronic acid infiltration within the previous 6 months;

  • Presented with chronic pain other than osteoarthritis, with scheduled surgery related to knee osteoarthritis;

  • regulatory reason (guardianship or already enrolled in a clinical trial).

Contacts and Locations

Locations

Site City State Country Postal Code
1 CEN Dijon France 21000

Sponsors and Collaborators

  • CEN Biotech
  • COMPAGNIE EUROPEENNE DES BAINS

Investigators

  • Study Director: Arnaud TERRILLON-SEYTRE, CEN

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CEN Biotech
ClinicalTrials.gov Identifier:
NCT05819437
Other Study ID Numbers:
  • C1650
First Posted:
Apr 19, 2023
Last Update Posted:
Apr 19, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by CEN Biotech
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2023